DrugPatentWatch Database Preview
Prasterone - Generic Drug Details
see a sample report or, see our see our flat-rate plans
What are the generic sources for prasterone and what is the scope of prasterone patent protection?
Prasterone
is the generic ingredient in one branded drug marketed by Amag Pharms Inc and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Prasterone has forty-eight patent family members in twenty-seven countries.
There are seven drug master file entries for prasterone. One supplier is listed for this compound.
Summary for prasterone
| International Patents: | 48 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 7 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 73 |
| Clinical Trials: | 7 |
| Patent Applications: | 5,716 |
| DailyMed Link: | prasterone at DailyMed |
Synonyms for prasterone
| (+)-Dehydroisoandrosterone |
| (1S,2R,5S,10R,11S,15S)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-en-14-one |
| (1S,2R,5S,10R,11S,15S)-5-HYDROXY-2,15-DIMETHYLTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADEC-7-EN-14-ONE |
| (1S,5S,11S,15S,2R,10R)-5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0<2,7>.0<11,15> ]heptadec-7-en-14-one |
| (3-beta)-3-Hydroxyandrost-5-en-17-one |
| (3beta)-3-hydroxyandrost-5-en-17-one |
| (3beta)-3-Hydroxyandrost-5-ene-17-one |
| (3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydro-17H-cyclopenta[a]phenanthren-17-one |
| (3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one |
| (3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-3,4,7,8,9,10,11,12,13,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17(2H)-one |
| 105597-37-3 |
| 108673-53-6 |
| 17-Chetovis |
| 17-Hormoforin |
| 1A9D2040-240C-427D-ADE4-0CB700B785CB |
| 3-|A-hydroxy-5-androsten-17-one |
| 3-beta-hydroxy-5-androsten-17-on |
| 3-beta-Hydroxy-5-androsten-17-one |
| 3-beta-hydroxyandrost-5-en-17-one |
| 3.beta.-Hydroxyandrost-5-en-17-one |
| 3beta-hydroxy-5-androsten-17-one |
| 3beta-Hydroxy-D5-androsten-17-one |
| 3beta-hydroxyandrost-5-en-17-one |
| 3beta-Hydroxyandrost-5-ene-17-one |
| 3beta-Hyroxyandrost-5-en-17-one |
| 4-08-00-00994 (Beilstein Handbook Reference) |
| 459AG36T1B |
| 5-Androsten-3.beta.-ol-17-one |
| 5-Androsten-3beta-ol-17-one |
| 5-Androsten-3beta-ol-17-one; DHEA |
| 5-Dehydroepiandrosterone |
| 5,6-Dehydroisoandrosterone |
| 5,6-Dehydroisoandrostorone |
| 5,6-didehydroepiandrosterone |
| 5,6-Didehydroisoandrosterone |
| 53-43-0 |
| 9013-35-8 |
| AB0007943 |
| AB00375810_09 |
| AB00375810-06 |
| AB1009532 |
| AC-28716 |
| AC1L1LC4 |
| ACT02646 |
| AJ-45664 |
| AK125048 |
| AKOS007930299 |
| AKOS015951378 |
| AN-24410 |
| Anastar |
| AND |
| Andrestenol |
| Androst-5-en-17-one, 3-beta-hydroxy- |
| Androst-5-en-17-one, 3-hydroxy-, (3-beta)- |
| Androst-5-en-17-one, 3-hydroxy-, (3-beta)- (9CI) |
| Androst-5-en-17-one, 3-hydroxy-, (3.beta.)- |
| Androst-5-en-17-one, 3-hydroxy-, (3b)- |
| Androst-5-en-17-one, 3-hydroxy-, (3beta)- |
| Androst-5-en-17-one, 3-hydroxy-, (3beta)- (9CI) |
| Androst-5-en-17-one, 3.beta.-hydroxy- |
| Androst-5-en-17-one, 3beta-hydroxy- |
| Androst-5-en-17-one, 3beta-hydroxy- (8CI) |
| Androst-5-ene-3beta-ol-17-one |
| Androstenolone |
| Aslera |
| Astenile |
| BCP9000602 |
| BCPE00002 |
| BCPP000260 |
| BDBM50223368 |
| BIDD:PXR0080 |
| Biolaif (TN) |
| bmse000665 |
| BRN 2058110 |
| C-18147 |
| C01227 |
| CAS-53-43-0 |
| Caswell No. 051F |
| CC-26313 |
| CCG-101190 |
| CCRIS 3277 |
| CHEBI:28689 |
| CHEMBL90593 |
| CMC_13435 |
| CS-1667 |
| D 4000 |
| D-0340 |
| D0044 |
| D00OAW |
| D08409 |
| D0K0EK |
| D5-Androsten-3beta-ol-17-one |
| DB01708 |
| Deandros |
| Dehydro-epi-androsterone |
| dehydroepiandrostenedione |
| Dehydroepiandrosternoe |
| Dehydroepiandrosterone |
| dehydroepiandrosterone (dhea) |
| Dehydroepiandrosterone, Neuroscience Pharma |
| Dehydroepiandrosterone, Paladin Labs |
| Dehydroisoandrosterone |
| Delta5-androsten-3-beta-ol-17-one |
| DHEA |
| DHEA (trans-Dehydroandrosterone) |
| DHEA, Neuroscience Pharma |
| DHEA, Paladin Labs |
| Diandron |
| Diandrone |
| DL-373 |
| DSSTox_CID_379 |
| DSSTox_GSID_20379 |
| DSSTox_RID_75553 |
| DTXSID4020379 |
| EBD1328208 |
| EC 200-175-5 |
| EINECS 200-175-5 |
| EL-10 |
| EM-760 |
| EPA Pesticide Chemical Code 126510 |
| Epiandrosterone, 5-dehydro- |
| EU-0100368 |
| Fidelin |
| Fidelin T |
| FMGSKLZLMKYGDP-USOAJAOKSA-N |
| GL 701 |
| GL-701 |
| GL701 |
| GS-0906 |
| GTPL2370 |
| HMS2052P11 |
| HMS2090C04 |
| HMS2232K11 |
| HY-14650 |
| Hydroxyandrost-5-en-17-one |
| IM 28 |
| Inflabloc |
| Intrarosa |
| IP-1001 |
| IPL-1001 |
| J10065 |
| LMST02020021 |
| Lopac0_000368 |
| LS-7296 |
| M-1336 |
| MFCD00003613 |
| MLS001066350 |
| MLS001333231 |
| MLS001333232 |
| MLS001424274 |
| MolPort-003-929-763 |
| NC00440 |
| NCGC00093802-04 |
| NCGC00093802-06 |
| NCGC00256412-01 |
| NCGC00259545-01 |
| NCI60_042215 |
| NSC 9896 |
| NSC-9896 |
| NSC9896 |
| PB-007 |
| PL000184 |
| Prasterona |
| Prasterona [INN-Spanish] |
| Prasterone (DHEA; Dehydroepiandrosterone) |
| Prasterone (DHEA; Dehydroepiandrosterone) 1.0 mg/ml in Acetonitrile |
| Prasterone (INN) |
| Prasterone [INN] |
| Prasterone [USAN:INN] |
| Prasteronum |
| Prasteronum [INN-Latin] |
| Prestara |
| Psicosterone |
| s2604 |
| SBB012501 |
| SCHEMBL24156 |
| SH-K-04828 |
| Siscelar plus |
| SMR000059075 |
| SR-01000075815 |
| SR-01000075815-1 |
| ST069381 |
| Tox21_111222 |
| Tox21_111222_1 |
| Tox21_201996 |
| Tox21_302761 |
| TR-018899 |
| trans-de-hydroandrosterone |
| trans-Dehydroandrosterone |
| trans-Dehydroandrosterone, >=99% |
| UNII-459AG36T1B |
| Vaginorm |
| Z2213891300 |
| ZINC3807917 |
US Patents and Regulatory Information for prasterone
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amag Pharms Inc | INTRAROSA | prasterone | INSERT;VAGINAL | 208470-001 | Nov 16, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Amag Pharms Inc | INTRAROSA | prasterone | INSERT;VAGINAL | 208470-001 | Nov 16, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Amag Pharms Inc | INTRAROSA | prasterone | INSERT;VAGINAL | 208470-001 | Nov 16, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Amag Pharms Inc | INTRAROSA | prasterone | INSERT;VAGINAL | 208470-001 | Nov 16, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
see a sample report or, see our see our flat-rate plans
see a sample report or, see our see our flat-rate plans
International Patents for prasterone
| Country | Document Number | Estimated Expiration |
|---|---|---|
| South Korea | 101680287 | ➤ Sign Up |
| Argentina | 104577 | ➤ Sign Up |
| Taiwan | 201634051 | ➤ Sign Up |
| China | 102861335 | ➤ Sign Up |
| Japan | 5725283 | ➤ Sign Up |
| Norway | 20100300 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
